About Us

Biocytogen: Innovative Models to Empower Antibody Discovery

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with top pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

BioMice

At Biocytogen, we have over 1200 genetically modified strains of BioMice that have assisted many of the top pharmaceutical companies with their R&D projects.

Our Missions

  • Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
  • Develop technological platforms to accelerate next-generation drug discovery and development
  • Empower scientists in drug discovery by providing the necessary expertise to eliminate bottlenecks in research
  • Be a global leader in providing seamless preclinical services to our clients

Our Milestones

Sept 2022
HKEX Listing
March 2022
Expansion
June 2021
Phase II
June 2021
New Financing
Sept 2020
RenMice
August 2020
Merger
Biocytogen & Eucure
Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.
May 2020
Clinical Trials
YH001 & YH002 Approved
Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China
March 2020
Platform Launch
RenMice HiTS Platform Launch
RenMice HiTS Platform initiative launched, signifying Biocytogen's transformation to a biotechnology company
January 2020
Clinical Trials
YH002 Clinical Trials Approved in U.S.
Anti-OX40 antibody YH002 was approved for clinical trials in the United States
October 2019
Clinical Trials
YH001 Clinical Trials Approved in U.S.
Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States
August 2019
New Technology
Rise of RenMab
Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
April 2018
Scaling Up
Venture Funding
Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
February 2018
New Sites
Boston & Shanghai Sites
Boston and Shanghai sites opened for business
2016
Company Matures
Haimen Animal Center Opens
Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
2016
Company Expansion
Preclinical Services & New Funding
Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
2014
Mouse Models
New Mouse Models Developed
Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
2011
Gene Editing
ESC/HR Gene Editing Platform
Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer.
2009
Origins
Biocytogen Established

Beijng Biocytogen Co., Ltd (Headquarters) established

Back to top